Test Price
2,800 AED✅ Home Collection Available
LZTFL1 Gene Bardet‑Biedl Syndrome Genetic Test | 2,800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited NGS processing covering all coding exons at ≥30x read depth.
Premium Logistics: VIP mobile phlebotomy with temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post‑test consultation with a consultant medical geneticist to interpret results and guide next steps.
Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731 – we confirm coverage before your sample draw.
Test Overview & Methodology
This next‑generation sequencing test thoroughly examines the entire coding region of the LZTFL1 gene to identify pathogenic variants linked to Bardet‑Biedl syndrome, a rare ciliopathy affecting the kidneys, eyes, liver, and endocrine system. The assay detects single‑nucleotide variants, small insertions/deletions, and copy‑number alterations with high analytical sensitivity.
| Feature | LZTFL1 NGS Test | Single‑Gene Sanger Alternative |
|---|---|---|
| Precision | 100% covered regions at ≥30x read depth | May miss deep intronic or large deletion variants |
| Methodology | Next‑Generation Sequencing – all exons analysed simultaneously | Sanger sequencing – one exon at a time, lower throughput |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
Physician Insight & Safety Protocols
“As a DHA‑licensed consultant medical geneticist, I emphasize that LZTFL1 mutations can mimic other multisystem disorders. A three‑generation family pedigree and thorough clinical correlation are essential before attributing symptoms to this gene. Genetic results should always be integrated with specialist consultation and never used as a standalone diagnostic tool.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication & Clinical Precautions
⚠ Medication Advisory: Do not discontinue or alter any prescribed medication without first consulting your treating physician. Genetic findings do not independently change existing treatment plans until reviewed by a qualified clinician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals with known severe bleeding disorders without haematologist clearance should not undergo venipuncture. Patients under 18 years require written parental or legal guardian consent.
- Emergency Red Flags: Severe dizziness, vasovagal syncope, or bleeding that persists beyond ten minutes after phlebotomy warrants immediate emergency medical attention.
- If pre‑test anxiety is extreme, schedule an in‑clinic blood draw under direct medical supervision.
Patient FAQ & Clinical Guidance
1. What is the LZTFL1 Bardet‑Biedl syndrome NGS test?
This genetic test sequences your LZTFL1 gene to detect pathogenic variants that cause Bardet‑Biedl syndrome, delivering 99.9% diagnostic accuracy across all coding exons and splice sites.
2. Who should consider this LZTFL1 gene analysis?
Individuals presenting with clinical features of Bardet‑Biedl syndrome – including retinitis pigmentosa, truncal obesity, postaxial polydactyly, renal anomalies, and learning difficulties – or those with a documented family history of the condition should pursue testing.
3. How do the results influence health management?
A positive result confirms the diagnosis and enables proactive surveillance for renal impairment, vision loss, and metabolic complications. A negative result does not rule out all forms of the syndrome and may warrant broader panel or whole‑exome sequencing.
UAE Regulatory & Data Privacy Adherence
Data Protection Framework: All genetic data is processed and stored in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic information is encrypted, access‑controlled, and never shared with third parties without explicit consent.
Clinical Safety & Patient Consent: Sample collection and handling adhere to the standards set by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Written informed consent is obtained before every genetic analysis, and you retain the right to withdraw consent at any stage.
Clinical & Logistical Metadata
| Test Name | LZTFL1 Gene Bardet‑Biedl Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Coding Region & Splice Sites |
| ICD-10-CM Code | Q87.89 |
| LOINC Code | 94305-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians